The Board of Directors of the Company, at its meeting held today i.e. Friday, May 29, 2026 appointed Mrs. Ekta Gupta as Independent Director(Additional) of the company.
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech's Board approved FY2026 standalone and consolidated audited results with an unmodified opinion from BSR & Co. LLP. Revenue declined to Rs 1,05,507 lakhs from Rs 1,20,009 lakhs in FY25, while profit after tax fell to Rs 26,327 lakhs from Rs 37,296 lakhs, impacted by lower operational income and new labour code provisions (Rs 328 lakhs exceptional item). EPS stood at Rs 25.17 vs Rs 35.65 in prior year. The Board recommended a dividend of Rs 7.55 per share (record date July 24, 2026). Mrs. Ekta Gupta, with MBA in Finance from Cardiff University and experience across finance, hospitality, and manufacturing sectors, was appointed as Additional Independent Director for 5 years from June 1, 2026, subject to shareholder approval. New internal auditor (Manubhai & Shah LLP) and cost auditor (Dalwadi & Associates) were appointed for FY27.
The profit decline may concern near-term investors, though the appointment of a new independent director and consistent dividend payout signal continued board stability and governance focus.